clinical trial · NCT06400121
Apimostinel + Automated Neurocognitive Training for Depression
Rebecca Price·phase2·recruiting·n = 150
DepressionApimostinel Infusion, IntravenousCognitive TrainingSham TrainingIsotonic Solution, Intravenous
brief summary
Apimostinel shows initial promise as a novel rapid-acting antidepressant medication with minimal side effects or safety concerns. Cognitive Training (CT) is a digital intervention that has shown promise in extending the durability of another similar drug (ketamine). This randomized controlled trial will test the efficacy and safety of apimostinel (vs. placebo) for the acute treatment of depression, and will test the potential of CT to enhance and/or extend the durability of apimostinel's antidepressant effect.
started
Oct 28, 2024
primary completion
Mar 1, 2029
completion
Dec 1, 2029
last updated
Sep 24, 2025
official title
Phase 2, Randomized, Double-Blind, Placebo-Controlled, Single Intravenous Dose, Parallel Efficacy Study of Apimostinel With or Without Subsequent Automated Self-Association Training in Subjects With Major Depressive Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol